Dr. Terence Tan presented an integrated approach to weight management and semaglutide therapy at the Society of Aesthetic Medicine 2026 conference in Singapore.

The introduction of the weight-loss drug Semaglutide in tablet form is expected to further transform medicine, following the impact of the injectable version, raising questions about its broader adoption.

Dr Reddy's CEO Erez Israeli anticipates strong performance in the second half of FY2026-27 once the company resolves its semaglutide supply issues, noting the highly competitive generics market for the drug.

Neurologists are warning that GLP-1 weight-loss drugs like semaglutide (Ozempic, Wegovy) may accelerate the progression of ALS by triggering dangerous rapid weight loss in patients with brain disorders.

India's Dr Reddy's Laboratories is experiencing its worst trading day in three years following disruptions in the supply of semaglutide.

New data from pharmaceutical company Novo Nordisk indicates that Wegovy (semaglutide 2.4 mg and 7.2 mg) provides significant and consistent weight loss results in women with obesity across all reproductive stages.

Hims has begun offering Apotex's generic version of semaglutide in Canada, following the expiration of Novo's patent for the drug.

Approximately 90,000 Finns used semaglutide for obesity last year, with Finns spending 66 million of their own money on obesity medications, while pharmaceutical companies' attempts to get obesity drugs covered by Kela reimbursements have been unsuccessful.

The introduction of the first Ozempic generics in Canada is expected to serve as a test case for Novo Nordisk, potentially marking the beginning of a decline in international revenue for semaglutide.

A Lancet study indicates that the weight-loss drug semaglutide could have an unexpected benefit, potentially helping individuals decrease their alcohol intake.

A study published in Nature identified a specific genetic variant that may enhance the effectiveness of GLP-1 weight-loss drugs such as semaglutide and tirzepatide.

Scientists have discovered that GLP-1 analogs, popular drugs for treating type 2 diabetes, do not have the same effect on all patients. Genetic factors may be responsible for why semaglutide-containing preparations are less effective for some individuals.

A report indicates that the availability of inexpensive semaglutide copies in India is posing a significant challenge to pharmaceutical giants Novo Nordisk and Eli Lilly, potentially eroding their market lead.

India is poised to enter the semaglutide market with affordable weight-loss drugs, with analysts predicting a potential billion-dollar market if priced and implemented correctly.

The FDA has approved Wegovy HD, a higher-dose semaglutide, for weight loss in adults with obesity, promising greater weight reduction despite expert warnings about potential side effects.

Namita Joshi made a New Year’s resolution in January to tackle one of her long-standing problems: being overweight.

The weight loss jabs Ozempic, Mounjaro and Weg­ovy — a type of medicine containing semaglutide — are increasingly being seen as a medical wonder of the age.

The weight-loss jab Wegovy may carry the highest risk of sudden sight loss compared to other semaglutide drugs such as Ozempic, according to new analysis.

The upcoming patent expiry for Ozempic in India is set to dramatically lower the cost of semaglutide, making this once-premium diabetes and weight-loss drug accessible to more patients. This shift could reshape the market, prompting earlier prescriptions and potentially altering societal views on weight management and body acceptance.

The European Commission has approved a new 7.2 mg weekly maintenance dose of Wegovy (semaglutide injection) for adults with obesity, providing an additional therapeutic option for those requiring greater weight loss.

CoreAge Rx has launched new weight reset coaching and education programs, expanding its weight and metabolic health offerings. These programs aim to maximize patient success with affordable, doctor-guided GLP-1 medications like Semaglutide and Tirzepatide.

The active ingredient Semaglutide, used in weight-loss medication, has received EU-wide approval for its tablet form, offering an alternative to injections.

A Greek article discusses how semaglutide can help manage obesity by reducing persistent thoughts about food, a phenomenon referred to as 'food noise'.

Dr. Reddy's Laboratories announced a delay in the supply of Semaglutide but clarified that there is no risk of a product recall.

An article discusses Ozempic and Wegovy, two medications containing the same active substance, semaglutide, but highlights their distinct intended uses and applications.

Scientists are exploring the potential effects of the drug Ozempic (semaglutide), suggesting it may be capable of reshaping the brain.

Hims & Hers has announced the launch of generic versions of Novo's semaglutide in Canada. This move expands access to the medication in the Canadian market.

Cheaper, generic versions of semaglutide have taken a significant share of the Indian market, impacting the sales of original manufacturer Novo Nordisk. Despite the competition, Novo Nordisk is maintaining its position.

A small study found that diabetes and weight-loss medications containing semaglutide helped individuals with alcohol abuse drink less, strengthening evidence for its potential to reduce cravings.

Dr. Reddy’s Laboratories has announced the rollout of its injectable semaglutide under the brand name Obeda®.

China is poised to initiate a price war for weight-loss drugs, particularly GLP-1 related treatments like semaglutide, as key patents begin to expire and the country's pharmaceutical industry can produce these treatments at scale.

Recent advancements in semaglutide and tirzepatide-based medications have transformed obesity management, but genetic factors may explain why these weight loss injections yield better results for some individuals than others.

The patent for semaglutide, the active ingredient in Ozempic and Wegovy, expired in several countries, leading to a surge of cheap generic versions in Asia. This development has raised concerns about potential weight-loss abuse.

Experts are emphasizing the need for a comprehensive, holistic framework to guide the use of Semaglutide, a medication commonly known as Ozempic, for weight management.

India's drug regulator is conducting inspections of both physical stores and online pharmacies to identify and address the unauthorized sale of semaglutide, a medication used for diabetes and weight loss.

A generic semaglutide shot is now available in India for Rs 1,296 per month, a cost reduction welcomed by top diabetologists with a word of caution.

Drugs such as semaglutide may be useful for mental health conditions associated with diabetes, authors say Diabetes drugs could prevent anxiety and depression from worsening, according to…

Researchers reveal that generic injectable semaglutide, the main ingredient in Ozempic and Wegovy, could cost between $28 and $140 (about 24 and 121 euros) per year.

‘Eye strokes’ that reduce blood flow to optic nerve likely to be side-effect of active ingredient semaglutide, says author Patients taking Wegovy have nearly five times the risk of sudden sight loss…

Cheap semaglutide, the drug in Ozempic and Wegovy, could help millions with diabetes and obesity in 160 countries Weight-loss jabs such as Wegovy and Ozempic could be made for just $3 a month,…

The European Commission has approved a 7.2 mg once-weekly injectable dose of semaglutide for adults living with obesity, following clinical trials that showed up to a 21% reduction in body weight.

CoreageRx has launched four new supplements aimed at muscle, digestion, and GLP-1 support, alongside advanced preventive longevity protocols. These new offerings include microdosing Semaglutide, Tirzepatide, and Sermorelin therapies.

Ozempic may play an important role in the fight against alcohol in the future, as according to recent research, drugs containing the active ingredient semaglutide may have beneficial effects in this area as well.

India's drug regulator, CDSCO, has granted approval for Novo Nordisk's weight-loss drug Wegovy (semaglutide injection 2.4 mg) to treat noncirrhotic metabolic dysfunction associated steatohepatitis (MASH) in adults.

Vivani Medical is innovating a tiny implant containing semaglutide, the active ingredient in popular obesity and diabetes medications, as a new method to help patients sustain weight loss.

The patent protection for semaglutide, a popular active ingredient in weight loss medications, has expired this year, which is anticipated to lead to a significant drop in prices, making it more accessible to millions.

Novo Nordisk presented encouraging new data at the European Congress on Obesity, indicating up to 27.7% weight loss with a new high dose of semaglutide (Wegovy).

Studies indicate that semaglutide tablets, which mimic natural GLP-1 agonists, are making weight loss significantly easier, especially for those needing to lose substantial amounts of weight, by reducing appetite.

Daewoong Pharmaceutical and TionLab Therapeutics have signed a strategic partnership to jointly develop and commercialize a long-acting monthly semaglutide injectable for the global market.

A study found that diabetes and weight-loss medication containing semaglutide helped individuals with alcohol use disorder reduce their alcohol consumption.

A new study suggests that individuals with a common gene variant, associated with a sweet tooth, may lose weight more effectively using the slimming drug semaglutide (Wegovy). This discovery could pave the way for personalized weight loss treatments.

The European Medicines Agency (EMA) has approved updated conditions for injectable semaglutide, used for obesity treatment, allowing it to be stored for up to 48 hours at temperatures up to 30°C during the final stage of delivery to patients.

Eli Lilly is losing market share in India's GLP-1 market due to the influx of cheap semaglutide generics, while Novo Nordisk maintains its position through price cuts for Ozempic and Wegovy.

India's patent for semaglutide is set to expire on March 20, leading to expectations that approximately 50 branded generic weight-loss drugs will enter the market.

The FDA has approved Wegovy HD, a higher-dose semaglutide, for weight loss in adults with obesity, offering a 'major jump' in potential weight reduction, with some users losing an average of 21 percent of their body weight.

The generic drugmakers, with many more expected to make announcements, are eyeing a share of the market for Semaglutide in India, which is estimated to be $1 billion over the next couple of years

With India’s semaglutide patent expiring on 20 March, about 50 branded generics are expected to enter the market.

New research suggests that popular diabetes and obesity drugs, such as semaglutide, may aid heart regeneration after a heart attack.

Strive Pharmacy says it will not resume compounded oral semaglutide sales  Reuters

Indian pharmaceutical companies Eris Lifesciences and Natco Pharma have entered into an agreement concerning the drug Semaglutide.